[Assessment of CYP2D6 activity as a form of optimizing antidepressant therapy]

Area of Science:

• Pharmacogenomics
• Drug Metabolism
• Enzyme Kinetics

Context:

• Cytochrome P450 2D6 (CYP2D6) is a key enzyme in the metabolism of numerous antidepressants, including TCAs and SSRIs.
• CYP2D6 exhibits significant genetic polymorphism, leading to distinct metabolic phenotypes: poor (PM), intermediate (IM), extensive (EM), and ultrarapid (UM).
• These variations can result in clinically significant consequences, such as drug toxicity or lack of therapeutic efficacy.

Purpose:

• To elucidate the clinical implications of CYP2D6 genetic polymorphism in antidepressant therapy.
• To describe the methods for assessing CYP2D6 activity, including phenotyping and genotyping.
• To highlight the importance of CYP2D6 phenotype knowledge in specific patient populations.

Summary:

• CYP2D6 genetic polymorphism dictates antidepressant metabolism, classifying individuals into four phenotypes (PM, IM, EM, UM).
• Poor or intermediate metabolizers may experience increased drug concentrations and toxicity, while ultrarapid metabolizers might show reduced efficacy.
• Phenotyping (using model drugs) and genotyping (allele identification) are methods to determine CYP2D6 status, with genotyping unaffected by environmental factors.

Impact:

• Knowledge of CYP2D6 phenotype is vital for personalized medicine, particularly for drugs with a narrow therapeutic index.
• Informing clinical decisions for polymedicated and elderly patients can prevent adverse drug reactions and improve treatment outcomes.
• Tailoring antidepressant selection and dosage based on CYP2D6 genotype can enhance therapeutic effectiveness and patient safety.